Cipla Ltd. has announced that the United States Food and Drug Administration (USFDA) conducted an inspection at its wholly-owned subsidiary, Medispray Laboratories Private Limited, in Kundaim, Goa, from January 14 to January 20, 2025.
Upon conclusion of the inspection, Medispray received one observation in Form 483. Cipla has stated its commitment to addressing the observation comprehensively within the stipulated timeframe while working closely with the USFDA.
The company has assured stakeholders that it will take necessary measures to resolve the issue, reinforcing its adherence to global regulatory standards.
This update comes as part of Cipla’s ongoing compliance under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
